Mothilal 2013.

Methods	A randomised prospective study with two parallel arms. Women randomised individually.
Participants	Inclusion criteria Women undergoing CS ‐ elective, non‐elective in labour and emergency. N = 70. Exclusion criteria Women who had signs of obvious infection, suspected renal impairment by history or lab evidence, who has known drug hypersensitivity to Azithromycin or Cephalosporin, who were recently administered with antibiotics, diabetic and anaemic pregnant women.
Interventions	Intervention: macrolide (E). 500 mg of Azithromycin. Half an hour prior to the surgery. Total number randomised: N = 35. Comparison: cephalosporin (B1). 1 g of Cefazolin. Half an hour prior to the surgery. Total number randomised: N = 35.
Outcomes	Reported outcomes: post‐operative fever, wound healing duration (healing within 10 days, healing within 20 days), pain for 6 days, pain for 7‐9 days, infection, PV discharge.
Notes	Study dates: September 2011 to February 2012. Follow‐up of the cases were finished in March 2012. Setting: Department of Obstetrics & Gynaecology, SRM Medical Research Centre and Hospital in Kattankulathur, Kancheepuram District, India. Subgroups Both elective and non‐elective CS. Before cord clamping. Systemic. Single dose. Comparison 14. No information about funding source of study.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	“The pregnant women were randomly given either Azithromycin or cefazolinas prophylactic antibiotics” and "(Antibiotics) were given ... in a random order ...”.
Allocation concealment (selection bias)	Unclear risk	"The pregnant women were randomly given either Azithromycin or Cefazolinas prophylactic antibiotics".
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information on this.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information on this.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No losses of follow‐up were reported.
Selective reporting (reporting bias)	Unclear risk	The study protocol is not available.
Other bias	Unclear risk	Not known. No information about funding source of study.